|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Pharmasset
|
|
gptkbp:awarded
|
gptkb:Prix_Galien_USA_(2016,_for_Harvoni)
gptkb:Prix_Galien_USA_(2017,_for_Epclusa)
|
|
gptkbp:businessModel
|
public
|
|
gptkbp:CEO
|
gptkb:Daniel_O’Day
|
|
gptkbp:competitor
|
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:AbbVie
gptkb:Bristol_Myers_Squibb
GlaxoSmithKline
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
gptkb:COVID-19
gptkb:hepatitis_C
gptkb:HIV/AIDS
gptkb:hepatitis_B
oncology
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:headquartersLocation
|
gptkb:Foster_City,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead Sciences, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:legalForm
|
gptkb:company
|
|
gptkbp:marketCap
|
~$90 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
|
|
gptkbp:netIncome
|
$5.3 billion (2023)
|
|
gptkbp:notableEmployee
|
gptkb:John_C._Martin
gptkb:John_F._Milligan
gptkb:Norbert_Bischofberger
|
|
gptkbp:notableInvention
|
gptkb:remdesivir
gptkb:sofosbuvir
gptkb:tenofovir_alafenamide
|
|
gptkbp:numberOfEmployees
|
~17,000 (2023)
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:product
|
gptkb:Descovy
gptkb:Biktarvy
gptkb:Harvoni
gptkb:Remdesivir
gptkb:Sovaldi
gptkb:Truvada
gptkb:Veklury
|
|
gptkbp:revenue
|
$27.1 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Immunomedics
gptkb:Kite_Pharma
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.gilead.com/
|
|
gptkbp:bfsParent
|
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
5
|